Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.

Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC.

Front Psychol. 2011 Jul 7;2:159. doi: 10.3389/fpsyg.2011.00159. eCollection 2011.

2.

Depression: the case for a monoamine deficiency.

Delgado PL.

J Clin Psychiatry. 2000;61 Suppl 6:7-11. Review.

3.

[Domino principle--monoamines in bottom-view].

Sümegi A.

Neuropsychopharmacol Hung. 2008 Jun;10(3):131-40. Review. Hungarian. Erratum in: Neuropsychopharmacol Hung. 2009 Sep;11(3):149.

4.

Monoamine neurocircuitry in depression and strategies for new treatments.

Hamon M, Blier P.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54-63. doi: 10.1016/j.pnpbp.2013.04.009. Epub 2013 Apr 19. Review.

PMID:
23602950
5.

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.

Bymaster FP, McNamara RK, Tran PV.

Expert Opin Investig Drugs. 2003 Apr;12(4):531-43. Review.

PMID:
12665410
6.
7.

[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].

Vignau J, Karila L, Costisella O, Canva V.

Encephale. 2005 May-Jun;31(3):349-57. Review. French.

PMID:
16142050
8.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
9.

An adaptationist perspective on the etiology of depression.

Durisko Z, Mulsant BH, Andrews PW.

J Affect Disord. 2015 Feb 1;172:315-23. doi: 10.1016/j.jad.2014.09.032. Epub 2014 Sep 28. Review.

PMID:
25451432
10.

Central monoamines and their role in major depression.

Elhwuegi AS.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):435-51. Review.

PMID:
15093950
11.

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies.

Ruhé HG, Mason NS, Schene AH.

Mol Psychiatry. 2007 Apr;12(4):331-59. Epub 2007 Jan 16. Review.

PMID:
17389902
12.

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.

Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Review.

PMID:
18501566
13.

Role of norepinephrine in depression.

Delgado PL, Moreno FA.

J Clin Psychiatry. 2000;61 Suppl 1:5-12. Review.

14.

The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.

Quesseveur G, Gardier AM, Guiard BP.

Curr Drug Targets. 2013 Oct;14(11):1277-94. Review.

PMID:
24020973
15.

Antidepressants for the treatment of depression in people with cancer.

Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M.

Cochrane Database Syst Rev. 2015 Jun 1;(6):CD011006. doi: 10.1002/14651858.CD011006.pub2. Review.

PMID:
26029972
16.

Duloxetine pharmacology: profile of a dual monoamine modulator.

Karpa KD, Cavanaugh JE, Lakoski JM.

CNS Drug Rev. 2002 Winter;8(4):361-76. Review.

17.

Inflammation, serotonin and major depression.

Catena-Dell'Osso M, Rotella F, Dell'Osso A, Fagiolini A, Marazziti D.

Curr Drug Targets. 2013 May 1;14(5):571-7. Review.

PMID:
23531160
18.

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.

Trivedi MH, Hollander E, Nutt D, Blier P.

J Clin Psychiatry. 2008 Feb;69(2):246-58. Review.

PMID:
18363453
19.

Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.

Thomas SJ, Shin M, McInnis MG, Bostwick JR.

Pharmacotherapy. 2015 Apr;35(4):433-49. doi: 10.1002/phar.1576. Review.

20.

[Mechanism of action of antidepressants and therapeutic perspectives].

Bourin M, David DJ, Jolliet P, Gardier A.

Therapie. 2002 Jul-Aug;57(4):385-96. Review. French.

PMID:
12422559

Supplemental Content

Support Center